Navigation Links
Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium
Date:7/20/2009

THOUSAND OAKS, Calif., July 20 /PRNewswire-FirstCall/ -- From July 18-20, more than 260 of the country's brightest undergraduate students met at UCLA for the third annual Amgen Scholars U.S. Symposium designed to bring together program participants and help them apply their science research experiences into future science careers.

The three-day symposium is a key component of the Amgen Scholars Program, a $27.5 million initiative that provides undergraduates the opportunity for hands-on research at some of the world's leading universities. During the symposium, hosted by the Amgen Foundation in collaboration with the Massachusetts Institute of Technology (MIT), students shared their summer research projects and heard firsthand from leading industry and academic scientists.

"More than ever before, we need to prepare and inspire the next generation of scientists to ensure the future of innovative discoveries," said Jean J. Lim, president of the Amgen Foundation. "The Amgen Foundation is committed to leading the way for the Amgen Scholars to learn about the many different scientific career paths available to them."

The 2009 Amgen Scholars, who have an average GPA of 3.73 were selected from more than 4,000 applications to participate in the Amgen Scholars U.S. Program and attend the mid-summer symposium. Under the mentorship of faculty members, the students - representing 136 schools from across 39 states and territories - are exploring areas of research beyond what they may be able to do as part of their regular undergraduate education.

"The Amgen Scholars Program is quickly becoming one of the most competitive summer research programs in the country," said Christopher M. Jones, director of the Amgen Scholars U.S. program office at MIT. "We are excited to see the Amgen Scholars alumni go on to pursue doctorates at leading universities and
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
2. Amgen Appoints Rebecca M. Henderson to the Companys Board of Directors
3. 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
4. AUDIO from Medialink and Amgen: Experts Agree Infection in Cancer Patients Impacts Treatment Success
5. Amgen to Present at the Goldman Sachs Global Healthcare Conference
6. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
7. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
8. Amgen Highlights Data to Be Presented at ASCO
9. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
10. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
11. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)...day announced the launch of International Solution... insurance plan which follows the acclaimed modula...ring customers the flexibility to add or remove a ...ets, International Solutions enables customers to ...offered in their country of residence. , ...
(Date:12/5/2009)...bines are popping up in the most unusual places, a... wine to keeping prisoners in jail! , ... have thought that your wine, water and vegetables...Fort Worth, Texas has announced a new line of turb...ing a technology developed to provide power for da...
(Date:12/4/2009)...tment Trust Inc. (NYSE: CRE ) ("Care" or the "C...rs has declared a dividend of $0.17 per share of c...22, 2009 to common shareholders of record on Decem...,, Care Investment Trust Inc. is a real estate inv...e-related real estate and commercial mortgage debt...
(Date:12/4/2009)...rive, Inc. has won the Patient,s Choice Award as t...ar vote conducted by the online website, www.weed... the SF Bay community has selected Medithrive as t...ijuana. ,, The rapid rise and popularity of Medi...ters to the consumer, provides a beautiful environ...
(Date:12/4/2009)...can Association of Homes and Services for the Agin...he Community Living and Supportive Services (CLASS...islation . The CLASS provisions are essential for ...ies and their caregivers. ,, We urge the Senate t... affordable to care for families and caregivers. ,...
Breaking Medicine News(10 mins):Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
...nal Toxicology Program (NTP), has produced strong ... chromium (chromium 6) causes cancer when it is c...omium compounds are often used in electroplating, ...veloped malignant tumors upon administration of th...
...low-dose tablet of aspirin daily to prevent blood ...cations such as pre-eclampsia. The review,...ound that taking aspirin had a 10 percent reduced ... aspirin appears to slightly increase the risk of ...
... today approved a proposed campaign to raise at le...st phase of UCSF Medical Center at Mission Bay. ...ated medical center to serve children, women and c... in 2014, the 865,000-plus-gross-square-foot hospi...
...tically monitored because not enough is known abou... group of scientists writing in todays British Med...ed foods which claim to improve health, quality of...g in popularity. Between January and April 2005 20...
...ever Limited (HLL) in Kodaikanal, a popular hill s..., traveled all the way to Bombay in western India ...ompanys share-holders to raise to raise the issues...nently its controversial thermometer plant at Koda...
...the California Department of Insurance and the Ora... fraud. These three are being accused of perf...ently billing more than $30 million to insurance c...ate insurance fraud scheme in which hundreds of pa...
Other Medicine News:Health News:UC Regents Approve Fundraised Campaign for UCSF Medical Center at Mission Bay 2Health News:Functional Foods Must Be Monitored to Assess Their Long-term Safety and Effectiveness 2Health News:Poisoned Workers of Hindustan Lever Demand Treatment 2Health News:Poisoned Workers of Hindustan Lever Demand Treatment 3Health News:Poisoned Workers of Hindustan Lever Demand Treatment 4Health News:Rent-A Body Scam Busted 2Health News:Rent-A Body Scam Busted 3
(Date:12/4/2009)...A, Md., Dec. 4 Northwest Biotherapeutics, Inc. ("... announced today that the US Patent and Trademark ...tem for automation of the initial stages of the ma... cancer vaccines. These initial manufacturing sta...ritic cells (which are the critical ingredient) in...
(Date:12/3/2009)...N, Mass., Dec. 3 Allen Medical Systems, a subsidi...ay announced the launch of its new Allen Amatech(T...website www.AllenAmatech.com . ,, The website ...d includes an online version of the new product ca...fications for the products. "We hope to make the n...
(Date:12/3/2009)...DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and ...www.quigleyco.com announced today that the Compan...s to develop prescription pharmaceutical and OTC p...nterests to focus primarily on the OTC/Personal Ca...ted to its Cold-EEZE® and Kids-EEZE® bra...
Breaking Medicine Technology:Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Study finds adverse effects in treatment for primary sclerosing cholangitis 54858 1Study finds adverse effects in treatment for primary sclerosing cholangitis 54858 2Researchers boost production of biofuel that could replace gasoline 9616 1Researchers boost production of biofuel that could replace gasoline 9616 2Breeding their horns off a winner 9614 1Breeding their horns off a winner 9614 2
...term safety and efficacy of TAXUS drug- ...ATICK, Mass., and WASHINGTON, Oct. 22 Boston,Scie...ive-year and final,follow- up data from its TAXUS ...d at years one through four -- in patients who rec...ronary Stent compared to patients who,received a b...
...ed Safety, Consistently Positive Clinical ..., Oct. 22 Data presented today from,Abbott,s SPIR...ntinued,positive, statistically significant clinic... Coronary Stent System at one year, including cont...c events (MACE) and continued,non- inferior rates ...
Other Medicine Technology:Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial 2Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial 3Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5
Sterile Individually Packed 100 mL Solution Basins
Serological Pipettes - 2 ml from TPP
...measuring pipettes, enables you to pipette safely,... with all types of glass or plastic pipettes in th... Aid is equipped with a safety valve and replaceab...f the device from contamination by the vapors of s...
Finnpipette BioMate Pipette Aid
Medicine Products: